DPP4 and fatty liver disease: Iwasaki et al. (2012) found a significant improvement of hemoglobin A1c (HbAlc), alanine aminotransferase, aspartate aminotransferase, and γ-gluten Aminoacyl transpeptidase in 30 patients with both fatty liver and type 2 diabetes mellitus (T2DM) after treatment by DPP4 inhibitor sitagliptin for 4 months.